2019
Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer
Pumpalova Y, Kozak MM, von Eyben R, Kunz P, Fisher G, Chang DT, Haraldsdottir S. Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. Journal Of Gastrointestinal Oncology 2019, 10: 605-615. PMID: 31392040, PMCID: PMC6657317, DOI: 10.21037/jgo.2019.02.17.Peer-Reviewed Original ResearchAnal cancer patientsIncidence of recurrenceAnal cancerDefinitive chemoradiationOverall survivalCancer patientsLonger recurrence-free intervalCancer-specific survivalDisease-specific survivalRecurrence-free intervalSignificant lower incidenceLoco-regional relapseLog-rank testMann-Whitney U testAnal painMore colostomiesLocoregional recurrencePatient characteristicsRectal cancerOverall incidenceGray's testLower incidenceCommon gradePatientsRecurrence
2018
A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.
Pumpalova Y, Kozak M, von Eyben R, Fisher G, Kunz P, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. Journal Of Clinical Oncology 2018, 36: 710-710. DOI: 10.1200/jco.2018.36.4_suppl.710.Peer-Reviewed Original ResearchAnal cancer patientsDisease-specific survivalCancer patientsFM groupCM groupDefinitive chemoradiationColostomy rateExact testCommon grade 2Higher colostomy rateIncidence of recurrenceLoco-regional recurrenceLog-rank testCause of deathFisher's exact testMann-Whitney U testAnal painInduction chemotherapyAnal cancerDefinitive radiotherapyDistant recurrenceOverall survivalMedian ageMost recurrencesRectal cancer
2012
Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-Term Survivors of Gastric Cancer: A California Population-Based Study. Journal Of Clinical Oncology 2012, 30: 3507-3515. PMID: 22949151, DOI: 10.1200/jco.2011.35.8028.Peer-Reviewed Original ResearchConceptsDisease-specific survivalMedian disease-specific survivalGEJ cancerGastric cancerIntestinal histologyAsian/Pacific Islander raceNational Cancer Institute's SurveillanceCox proportional hazards modelEsophagus/cardiaCalifornia Cancer RegistryPacific Islander raceGastroesophageal junction adenocarcinomaKaplan-Meier curvesEnd Results ProgramCases of gastricSocioeconomic status quintileProportional hazards modelJunction adenocarcinomaPathologic characteristicsTerm survivorsCancer RegistryTumor characteristicsDiffuse histologyHispanic raceResults Program
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply